What is HC Wainwright’s Estimate for Agenus Q2 Earnings?

Agenus Inc. (NASDAQ:AGEN) – Equities researchers at HC Wainwright dropped their Q2 2026 earnings per share estimates for Agenus in a research report issued to clients and investors on Monday, July 13th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will earn $0.05 per share for the quarter, down from their prior estimate of $0.06. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Agenus’ current full-year earnings is $0.83 per share. HC Wainwright also issued estimates for Agenus’ FY2026 earnings at $0.83 EPS, FY2027 earnings at ($0.16) EPS, FY2028 earnings at ($0.43) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at ($0.26) EPS.

Several other equities research analysts have also recently weighed in on the stock. Wall Street Zen upgraded shares of Agenus from a “hold” rating to a “buy” rating in a research report on Monday, April 6th. Zacks Research lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Agenus in a research note on Tuesday, June 16th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $30.00.

Agenus Stock Performance

NASDAQ AGEN opened at $5.00 on Wednesday. The company has a market capitalization of $208.20 million, a P/E ratio of 3.14 and a beta of 1.55. Agenus has a one year low of $2.71 and a one year high of $8.70. The stock has a 50 day moving average price of $3.42 and a 200-day moving average price of $3.47.

Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Monday, May 11th. The biotechnology company reported $1.02 earnings per share for the quarter, missing the consensus estimate of $2.10 by ($1.08). The firm had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $129.50 million. Agenus had a net margin of 50.49% and a negative return on equity of 31.66%.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently bought and sold shares of the business. EP Wealth Advisors LLC bought a new stake in shares of Agenus during the fourth quarter worth $31,000. Jump Financial LLC bought a new position in shares of Agenus in the second quarter worth about $55,000. R Squared Ltd purchased a new position in Agenus in the 4th quarter worth about $41,000. Squarepoint Ops LLC purchased a new position in Agenus in the 3rd quarter worth about $54,000. Finally, Redwood Family Wealth LLC bought a new stake in Agenus during the 4th quarter valued at about $44,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.